Sonia Tejada1, Marta Alonso2, Ana Patiño2, Juan Fueyo3, Candelaria Gomez-Manzano3, Ricardo Diez-Valle4. 1. Department of Neurosurgery, Clínica Universidad de Navarra (CUN), Pamplona, Spain. 2. Department of Pediatrics, Pro-gram of Solid Tumors, Center for the Applied Medical Research at University of Navarra, Pamplona, Spain. 3. Department of Neuro-Oncology, MD Anderson Cancer Center, Houston, Texas. 4. Neurosurgical Department, Clínica Universidad de Navarra (CUN), Pamplona, Spain.
Abstract
BACKGROUND: There are no effective treatments for diffuse intrinsic pontine gliomas (DIPGs); these tumors cannot be surgical resected, and diagnosis is based on magnetic resonance imaging. As a result, tumor tissues for molecular studies and pathologic diagnosis are infrequent. New clinical trials are investigating novel medications and therapeutic techniques in an effort to improve treatment of patients with DIPGs. OBJECTIVE: To determine the safety, tolerability, and toxicity of an oncolytic adenovirus, DNX-2401, injected into the cerebellar peduncle in pediatric subjects with DIPG and to collect tumor samples of this type of tumor. METHODS: Phase I, single-center, uncontrolled trial. A tumor biopsy will be performed through the cerebellar peduncle, and DNX-2401 will be injected immediately after the biopsy. Standard therapy consisting of radiotherapy and chemotherapy will follow in 2 to 6 wk. EXPECTED OUTCOMES: Improvement of overall survival and quality of life in patients with DIPG and collection of tumor specimens to study the molecular profiling of these tumors. DISCUSSION: The aims of this trial are to contribute to the sample collection of DIPG and to offer treatment during the tumor tissue biopsy using the virus. If this virus works as expected, it could kill the tumor cells with no damage to healthy tissue, functioning as a targeted therapy. It is important to note that edema has not been observed with this virus in all trials performed to date. The information obtained through this and other similar studies may be useful for developing or improving new therapies in the battle against DIPG.
BACKGROUND: There are no effective treatments for diffuse intrinsic pontine gliomas (DIPGs); these tumors cannot be surgical resected, and diagnosis is based on magnetic resonance imaging. As a result, tumor tissues for molecular studies and pathologic diagnosis are infrequent. New clinical trials are investigating novel medications and therapeutic techniques in an effort to improve treatment of patients with DIPGs. OBJECTIVE: To determine the safety, tolerability, and toxicity of an oncolytic adenovirus, DNX-2401, injected into the cerebellar peduncle in pediatric subjects with DIPG and to collect tumor samples of this type of tumor. METHODS: Phase I, single-center, uncontrolled trial. A tumor biopsy will be performed through the cerebellar peduncle, and DNX-2401 will be injected immediately after the biopsy. Standard therapy consisting of radiotherapy and chemotherapy will follow in 2 to 6 wk. EXPECTED OUTCOMES: Improvement of overall survival and quality of life in patients with DIPG and collection of tumor specimens to study the molecular profiling of these tumors. DISCUSSION: The aims of this trial are to contribute to the sample collection of DIPG and to offer treatment during the tumor tissue biopsy using the virus. If this virus works as expected, it could kill the tumor cells with no damage to healthy tissue, functioning as a targeted therapy. It is important to note that edema has not been observed with this virus in all trials performed to date. The information obtained through this and other similar studies may be useful for developing or improving new therapies in the battle against DIPG.
Authors: Sonia Tejada; Kristian Aquilina; John Goodden; Benedetta Pettorini; Conor Mallucci; Marie Lise van Veelen; Ulrich-W Thomale Journal: Childs Nerv Syst Date: 2020-02-04 Impact factor: 1.475
Authors: Jonathan G Pol; Sarah Lévesque; Samuel T Workenhe; Shashi Gujar; Fabrice Le Boeuf; Derek R Clements; Jean-Eudes Fahrner; Laetitia Fend; John C Bell; Karen L Mossman; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi Journal: Oncoimmunology Date: 2018-08-27 Impact factor: 8.110
Authors: James L Ross; Zhihong Chen; Cameron J Herting; Yura Grabovska; Frank Szulzewsky; Montserrat Puigdelloses; Lenore Monterroza; Jeffrey Switchenko; Nitin R Wadhwani; Patrick J Cimino; Alan Mackay; Chris Jones; Renee D Read; Tobey J MacDonald; Matthew Schniederjan; Oren J Becher; Dolores Hambardzumyan Journal: Brain Date: 2021-02-12 Impact factor: 13.501
Authors: Jessica B Foster; Peter J Madsen; Meenakshi Hegde; Nabil Ahmed; Kristina A Cole; John M Maris; Adam C Resnick; Phillip B Storm; Angela J Waanders Journal: Neuro Oncol Date: 2019-10-09 Impact factor: 12.300
Authors: Virginia Laspidea; Montserrat Puigdelloses; Sara Labiano; Lucía Marrodán; Marc Garcia-Moure; Marta Zalacain; Marisol Gonzalez-Huarriz; Naiara Martínez-Vélez; Iker Ausejo-Mauleon; Daniel de la Nava; Guillermo Herrador-Cañete; Javier Marco-Sanz; Elisabeth Guruceaga; Carlos E de Andrea; María Villalba; Oren Becher; Massimo Squatrito; Verónica Matía; Jaime Gállego Pérez-Larraya; Ana Patiño-García; Sumit Gupta; Candelaria Gomez-Manzano; Juan Fueyo; Marta M Alonso Journal: JCI Insight Date: 2022-04-08
Authors: Sonia Tejada; Ricardo Díez-Valle; Pablo D Domínguez; Ana Patiño-García; Marisol González-Huarriz; Juan Fueyo; Cande Gomez-Manzano; Miguel Angel Idoate; Joanna Peterkin; Marta M Alonso Journal: Front Oncol Date: 2018-03-12 Impact factor: 6.244
Authors: Maider Varela-Guruceaga; Sonia Tejada-Solís; Marc García-Moure; Juan Fueyo; Candelaria Gomez-Manzano; Ana Patiño-García; Marta M Alonso Journal: Cancers (Basel) Date: 2018-07-09 Impact factor: 6.639